These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38356434)

  • 41. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
    Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
    Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
    Pai RL; Japp AS; Gonzalez M; Rasheed RF; Okumura M; Arenas D; Pierson SK; Powers V; Layman AAK; Kao C; Hakonarson H; van Rhee F; Betts MR; Kambayashi T; Fajgenbaum DC
    JCI Insight; 2020 May; 5(9):. PubMed ID: 32376796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TAFRO syndrome is associated with anti-SSA/Ro60 antibodies, in contrast to idiopathic castleman disease.
    Shirakashi M; Nishida Y; Nakashima R; Fujimoto M; Hiwa R; Tsuji H; Kitagori K; Akizuki S; Morinobu A; Yoshifuji H
    Sci Rep; 2024 Feb; 14(1):2889. PubMed ID: 38311632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.
    Iwaki N; Gion Y; Kondo E; Kawano M; Masunari T; Moro H; Nikkuni K; Takai K; Hagihara M; Hashimoto Y; Yokota K; Okamoto M; Nakao S; Yoshino T; Sato Y
    Sci Rep; 2017 Feb; 7():42316. PubMed ID: 28205564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.
    Iwaki N; Fajgenbaum DC; Nabel CS; Gion Y; Kondo E; Kawano M; Masunari T; Yoshida I; Moro H; Nikkuni K; Takai K; Matsue K; Kurosawa M; Hagihara M; Saito A; Okamoto M; Yokota K; Hiraiwa S; Nakamura N; Nakao S; Yoshino T; Sato Y
    Am J Hematol; 2016 Feb; 91(2):220-6. PubMed ID: 26805758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic basis for iMCD-TAFRO.
    Yoshimi A; Trippett TM; Zhang N; Chen X; Penson AV; Arcila ME; Pichardo J; Baik J; Sigler A; Harada H; Fajgenbaum DC; Dogan A; Abdel-Wahab O; Xiao W
    Oncogene; 2020 Apr; 39(15):3218-3225. PubMed ID: 32051554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
    Lust H; Gong S; Remiker A; Rossoff J
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature.
    Zhou Q; Zhang Y; Zhou G; Zhu J
    BMC Nephrol; 2020 Nov; 21(1):499. PubMed ID: 33225930
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
    Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L
    Front Immunol; 2019; 10():1489. PubMed ID: 31316523
    [No Abstract]   [Full Text] [Related]  

  • 50. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
    Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
    J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy.
    Iwaki N; Sato Y; Takata K; Kondo E; Ohno K; Takeuchi M; Orita Y; Nakao S; Yoshino T
    J Clin Exp Hematop; 2013; 53(1):87-93. PubMed ID: 23801139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concordance between transbronchial lung cryobiopsy and surgical lung biopsy in patients with idiopathic multicentric Castleman disease: A report of four cases.
    Otoshi R; Kitamura H; Baba T; Muraoka T; Sekine A; Takemura T; Okudela K; Sawazumi T; Ogura T
    Respir Investig; 2024 Jan; 62(1):1-8. PubMed ID: 37925882
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.
    Nagy A; Bhaduri A; Shahmarvand N; Shahryari J; Zehnder JL; Warnke RA; Mughal T; Ali S; Ohgami RS
    Blood Adv; 2018 Mar; 2(5):481-491. PubMed ID: 29496669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease.
    Horna P; King RL; Jevremovic D; Fajgenbaum DC; Dispenzieri A
    Haematologica; 2023 Jan; 108(1):207-218. PubMed ID: 35484648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rheumatoid arthritis-like active synovitis with T-cell activation in a case of idiopathic multicentric Castleman disease: A case report.
    Otsuka M; Koga T; Sumiyoshi R; Okamoto M; Endo Y; Tsuji S; Takatani A; Shimizu T; Igawa T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Daisuke N; Kawakami A
    Medicine (Baltimore); 2019 May; 98(18):e15237. PubMed ID: 31045763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study.
    Nishimura Y; Hanayama Y; Fujii N; Kondo E; Otsuka F
    Intern Med J; 2020 Feb; 50(2):184-191. PubMed ID: 31211492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Delayed diagnosis of TAFRO syndrome: A case report.
    Qiao Y; Zhang X; Xu R; Jia X; Wang Q
    Medicine (Baltimore); 2024 Aug; 103(31):e39148. PubMed ID: 39093747
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Wu D; Goodman A; Wong R; Chadburn A; Nasta S; Srkalovic G; Mukherjee S; Leitch H; Jayanthan R; Ferrero S; Sato Y; Schey S; Dispenzieri A; Oksenhendler E; Zinzani PL; Lechowicz MJ; Hoffmann C; Pemmaraju N; Bagg A; Fossa A; Lim MS; van Rhee F;
    Am J Hematol; 2020 Dec; 95(12):1553-1561. PubMed ID: 32894785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Not Available].
    Bertinchamp R; Terriou L
    Rev Med Interne; 2022 Dec; 43(10S1):10S4-10S9. PubMed ID: 36657941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease.
    Harada T; Kikushige Y; Miyamoto T; Uno K; Niiro H; Kawakami A; Koga T; Akashi K; Yoshizaki K
    Nat Commun; 2023 Oct; 14(1):6959. PubMed ID: 37907518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.